InsideArbitrage Potential Deal Alert: MEI Pharma (MEIP) Confirms Receipt of Unsolicited Acquisition Proposal

POTENTIAL DEAL DETAILS

MEI Pharma (MEIP) confirmed receipt of an unsolicited and non-binding proposal from a group represented by Anson Advisors and Cable Car Capital to acquire all outstanding shares of MEI for not less than $8.00 in cash per share.

Update(s):

June 1, 2023: MEI Pharma, Inc. (MEIP) announced that its Board of Directors  reviewed and rejected the unsolicited and non-binding proposal received.

The Board concluded that the unsolicited proposal significantly undervalues the company, is not superior to the proposed transaction with Infinity Pharmaceuticals (INFI), and does not provide a basis for discussions regarding an alternative transaction.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.